Bergen, Norway, November 7th, 2023: Today, Lifecare AS (LIFE), a clinical
stage medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), announces that The Norwegian Food Safety Authority (NFSA) has
awarded all necessary approvals to start LFC-SEN-002.
Reference is made to Lifecare's list of trigger events, as presented at the
semi-annual report of August 20th, 2023, and later investor communication. The
launch of an automated production line at Lifecare Laboratory by end of Q2
2024 is set as a major milestone, and on this basis the company aim to launch
the first product in the veterinary market mid 2024.
The approval means that Lifecare can start working on the second study only
six months after finalizing the successful Sencell clinical study:
LFC-SEN-001. As previously communicated the LFC-SEN-002 will be carried out in
collaboration with The Norwegian University of Life Sciences (NMBU) located at
Ås, Norway. Lifecare has received approval from the authority to complete the
study on dogs. NFSA considers that the purpose of the experiment and the use
of animals are satisfactorily described in the application and that the
necessary requirements in the Laboratory Animal Regulations are met.
- We are very pleased to receive this approval. This is another important
piece in the development of the Sencell sensor. Earlier this year, we carried
out a longevity experiment of up to 6 months and showed through LFC-SEN-001
that the Sencell sensor has the required sensitivity. We are now very much
looking forward to soon start testing the technology in dogs for up to 90
days, says CEO Joacim Holter at Lifecare.
It is Managing Director Jo Amundstad in the subsidiary Lifecare Vetarinary who
will be responsible for carrying out the study in collaboration with NMBU. -
We are incredibly grateful for the collaboration with experts in internal
medicine at NMBU and we have already hired PhD candidate Sivert Nerhagen. We
have used the time well while waiting for the approval from the NFSA and are
well underway with recruiting patients for the study, says Amundstad.
About us
Lifecare AS is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body.
Contacts
For further information, please contact:
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
Asle Wingsternes, Head of Communications & Public Affairs,
asle.wingsternes@lifecare.no, +47 41 61 42 52
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2023-11-07 08:00 CET.